In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement Industry Waits For “Friendlier” MedWatch Form

This article was originally published in The Tan Sheet

Executive Summary

FDA changes MedWatch form 3500A to accommodate medical device firms’ needs, but will not make changes to facilitate reporting AERs for drug, supplement or food products. The agency and supplement industry stakeholders agree 3500A is not ideal for supplement AERs.

You may also be interested in...



Burton Bill Would Move Up New Dietary Ingredient Grandfather Date To 2007

Rep. Burton offers legislation to move up from 1994 to 2007 the date delineating old from new dietary ingredients. Despite the appeal, supplement trade groups are leery of opening up DSHEA to amendment.

FDA Says Supplement Adverse Event Under-Reporting Should Feed Growth

FDA published a how-to guide to push dietary supplement firms toward tighter compliance with the requirement to submit serious adverse event reports to the agency.

US DoJ Has 'Key Focus' On Supplement Industry, Adds 6 Attorneys To Sector

"It is just common sense that there's going to be fraud where you have the combination of high growth, developing science, imported products or ingredients and limited oversight," says David Morrell, deputy assistant US attorney in DoJ'd Consumer Protection Branch. CPB is adhering to executive order President Trump made earlier in 2019 instructing federal agencies to enforced based on regulations, not on guidance.

Topics

UsernamePublicRestriction

Register

PS105490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel